Both in Pharmaceuticals
Genelux vs Citius Oncology
Over the past year GNLX returned −42.4% and CTOR returned −48.3%; their daily moves had a correlation of 0.12.
GNLX −42.4% CTOR −48.3%Growth of $1, one year, split-adjusted
| Metric | GNLX | CTOR |
|---|---|---|
| Price | $2.45 | $1.05 |
| Market cap | $110.9M | $111.0M |
| Today | −0.81% | +1.94% |
| 1 month | −7.9% | +35.4% |
| 6 months | +6.5% | +113.0% |
| Year to date | −43.8% | +5.0% |
| 1 year | −41.7% | −47.5% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | 67.1% |
| Net margin | — | −597.4% |
| P/E (TTM) | — | — |
| Price / sales | 13,856.4× | 15.6× |
| Net cash | $18.7M | $10.2M |
| Dividend yield | — | — |
| Volatility (60d) | 53.7% | 99.9% |
| Short % of float | 10.7% | 1.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).